NCT03879057: Trial of Sulfatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

NCT03879057
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with evidence of active CNS disease; Patients with prior treatment of chemotherapy, biological immunotherapy, or targeted therapy- see trial for details
https://ClinicalTrials.gov/show/NCT03879057

Comments are closed.

Up ↑